Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting
JCO Oncology Practice · 2024
DOI: 10.1200/op.23.00630 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Bita Fakhri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Real-world evidence comparing health care resource use (HRU) and costs between novel targeted therapies among patients with chronic lymphocytic leukemia (CLL) is lacking. We compared all-cause and CLL-specific HRU and costs between patients initiated on B-cell lymphoma 2 inhibitor (venetoclax)– or Bruton tyrosine kinase inhibitor (BTKi)–based regimens in the second-line (2L) setting. METHODS This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January 2018-December 2021) for the first time and had ≥one CLL diagnostic claim after 2L initiation and ≥two claims for venetoclax or BTKi. Baseline characteristics were balanced using stabilized inverse probability of treatment weights. Mean monthly cost difference (MMCD) between cohorts for all-cause and CLL-specific per patient per month (PPPM) costs was estimated. Rates of PPPM-HRU were compared between cohorts using rate ratios (RRs). RESULTS Of 280 patients, median age 75.5 years, 64.6% and 35.4% received BTKi- versus venetoclax-based regimens, respectively. Most BTKi-treated patients received monotherapy (88.4%), whereas 62.3% of venetoclax-treated patients received combination therapy with anti-CD20 agents. The median duration of 2L therapy was 11.6 and 11.0 months for BTKi versus venetoclax cohorts, respectively. All-cause total costs were lower for venetoclax versus BTKi (MMCD [SE], $–2,497.64 [$1,006.77] in US dollars (USD); P = .01), driven by lower medication costs offsetting medical costs; trends were similar for CLL-specific estimates. Outpatient HRU was higher for venetoclax versus BTKi (RR all-cause: 1.22 versus CLL-specific: 1.64). CONCLUSION Venetoclax was associated with total monthly cost savings versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens in the 2L setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Stanford University, Stanford, CA.
- AbbVie, Inc, North Chicago, IL.
- Lowell General Hospital, Lowell, MA.
- Dana Farber Cancer Institute, Boston, MA.
ORCID-Profile: Bita Fakhri, Beenish S Manzoor, Hande H Tuncer
Zitieren
APA
Fakhri, B., Emechebe, N., Manzoor, B. S., Jawaid, D., Alhasani, H., Edwards, M., & Tuncer, H. H. (2024). Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting. JCO Oncology Practice. https://doi.org/10.1200/op.23.00630
Vancouver
Fakhri B, Emechebe N, Manzoor BS, Jawaid D, Alhasani H, Edwards M, et al. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting. JCO Oncology Practice. 2024. doi:10.1200/op.23.00630
BibTeX
@article{Fakhri2024,
author = {Fakhri, Bita and Emechebe, Nnadozie and Manzoor, Beenish S and Jawaid, Dureshahwar and Alhasani, Hasan and Edwards, Melanie and Tuncer, Hande H},
title = {Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting},
journal = {JCO Oncology Practice},
year = {2024},
doi = {10.1200/op.23.00630}
}
EUVIMED